Oncolytic virotherapy for malignant tumor: Current clinical status

Yuhui Zhang, Zhuoming Liu

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Oncolytic viruses, as novel biological anti-tumor agents, provide anti-tumor therapeutic effects by different mechanisms including directly selective tumor cell lysis and secondary systemic anti-tumor immune responses. Some wide-type and genetically engineered oncolytic viruses have been applied in clinical trials. Among them, T-Vec has a significant therapeutic effect on melanoma patients and received the approval of the US Food and Drug Administration (FDA) as the first oncolytic virus to treat cancer in the US. However, the mechanisms of virus interaction with tumor and immune systems have not been clearly elucidated and there are still no “gold standards” for instructions of virotherapy in clinical trials. This Review collected the recent clinical trials data from 2005 to summarize the basic oncolytic viruses biology, describe the application in recent clinical trials, and discuss the challenges in the application of oncolytic viruses in clinical trials.

Original languageEnglish
Pages (from-to)4251-4263
Number of pages13
JournalCurrent Pharmaceutical Design
Volume25
Issue number40
DOIs
StatePublished - 2019

Keywords

  • Cancer
  • Clinical trial
  • Genetically engineered
  • Malignant tumor
  • Oncolytic viruses
  • Virotherapy

Fingerprint

Dive into the research topics of 'Oncolytic virotherapy for malignant tumor: Current clinical status'. Together they form a unique fingerprint.

Cite this